SCHEMBL142610

SCHEMBL142610

CC(C#N)C/N=N/CC(C)C#N

nearest known ligand 0.43

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522065 1.00 TSHR (0.43) TSHR
SCHEMBL121 1.00 TSHR (0.43) TSHR
Hydrochloric Acid SCHEMBL9508593 0.97 TSHR (0.42) TSHR
SCHEMBL10454453 0.97 TSHR (0.42) TSHR
SCHEMBL4476401 0.92 TSHR (0.39) TSHR
Cyclohexane SCHEMBL9580757 0.92 TSHR (0.39) TSHR
Alcohol SCHEMBL11052439 0.89 TSHR (0.37) TSHR
SCHEMBL9860811 0.88 TSHR (0.46) TSHR
SCHEMBL7066390 0.86 TSHR (0.44) TSHR
Formamide SCHEMBL15106454 0.85 TSHR (0.34) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595265-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2026-04-07 US disclosed
WO-2025224249-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
WO-2025090727-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
US-20240308976-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-19 US disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-20240294495-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-05 US disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2024-05-16 US disclosed
WO-2024028169-A1 NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-02-08 WO disclosed
EP-4285996-A2 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2023-12-06 EP disclosed
US-4580627-A Oil recovery process and system MARATHON OIL COMPANY (US) 1986-04-08 US disclosed
WO-1985003696-A1 PROCESS FOR DILUTING AQUEOUS POLYMER SOLUTIONS MARATHON OIL COMPANY (US) 1985-08-29 WO disclosed
EP-0148581-A1 High solid coatings EXXON RESEARCH AND ENGINEERING COMPANY (US) 1985-07-17 EP disclosed
US-4517097-A Process for diluting aqueous polymer solutions MARATHON OIL COMPANY (US) 1985-05-14 US disclosed
US-4503909-A Oil recovery process and system MARATHON OIL COMPANY (US) 1985-03-12 US disclosed
US-4433727-A INJECTION OF AQUEOUS POLYMER SOLUTION AND MOBILITY BUFFER MARATHON OIL COMPANY (US) 1984-02-28 US disclosed
US-4397748-A PARTIALLY HYDROLYZED ADDITION POLYMER AS FLOW CONTROL AGENT MARATHON OIL COMPANY (US) 1983-08-09 US disclosed
US-4290485-A PARTIALLY HYDROLYSED POLYACRYLAMIDE, CROSSLINKING THE DOW CHEMICAL COMPANY (US) 1981-09-22 US disclosed
US-4165431-A Chlorination of polyolefins in the presence of complex formers BAYER AKTIENGESELLSCHAFT (DE) 1979-08-21 US disclosed
US-3945958-A WATER-SOLUBLE CELLULOSE ETHERS, VISCOSITY SHINETSU CHEMICAL COMPANY (JA) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 TSHR 1171/4885
US-20240294495-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CRBN, GSPT1, GSPT2 TSHR 2591/4885
US-20240308976-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF CRBN, GSPT1, GSPT2 TSHR 2520/4885
US-12595265-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVRL1, ACVR2A TSHR 126/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 TSHR 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.